TTF1 and non-small cell lung carcinoma: TTF-1 expression has been reported as a potential prognostic factor in patients with NSCLC and has also been previously reported to be significantly associated with therapeutic response to cytotoxic anticancer agents, particularly pemetrexed, with favorable results in TTF-1 positive patients (7, 8).